Analysis of the potent prognostic factors in luminal-type breast cancer

Journal of Breast Cancer

Volumn 15, Issue 4, 2012, Pages 401-406

  Kim, Han Sung ^a   Park, Inseok ^a   Cho, Hyun Jin ^a   Gwak, Geumhee ^a   Yang, Keunho ^a   Bae, Byung Noe ^a   Kim, Ki Whan ^a   Han, Sehwan ^a   Kim, Hong Joo ^a   Kim, Young Duck ^a  

^a Inje University College of Medicine   (South Korea)

Author keywords

Bcl 2; Breast neoplasms; Prognosis

Indexed keywords

ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN BCL 2;

ADULT; AGE; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER PROGNOSIS; DISEASE CLASSIFICATION; DISEASE FREE SURVIVAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TUMOR VOLUME;

EID: 84872285603     PISSN: 17386756     EISSN: None     Source Type: Journal    
DOI: 10.4048/jbc.2012.15.4.401     Document Type: Article

References (23)

1. Zaha DC, Lazǎr E, Lǎzureanu C. Clinicopathologic features and five years survival analysis in molecular subtypes of breast cancer. Rom J Morphol Embryol 2010;51:85-9.
2. Kröger N, Milde-Langosch K, Riethdorf S, Schmoor C, Schumacher M, Zander AR, et al. Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients. Clin Cancer Res 2006;12:159-68.
3. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009;101:736-50.
4. Brenton JD, Carey LA, Ahmed AA, Caldas C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol 2005;23:7350-60.
5. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn HJ; Panel members. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009;20:1319-29.
6. Ahlin C, Aaltonen K, Amini RM, Nevanlinna H, Fjällskog ML, Blomqvist C. Ki67 and cyclin A as prognostic factors in early breast cancer. What are the optimal cut-off values? Histopathology 2007;51:491-8.
7. Neri A, Marrelli D, Pedrazzani C, Caruso S, De Stefano A, Mariani F, et al. Prognostic relevance of proliferative activity evaluated by Mib-1 immunostaining in node negative breast cancer. Eur J Surg Oncol 2008; 34:1299-303.
8. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
9. Osborne CK. Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat 1998;51:227-38.
10. Hess KR, Pusztai L, Buzdar AU, Hortobagyi GN. Estrogen receptors and distinct patterns of breast cancer relapse. Breast Cancer Res Treat 2003;78:105-18.
11. Steroid receptors in breast cancer: an NIH Consensus Development Conference, Bethesda, Maryland, June 27-29, 1979. Cancer 1980;46: 2759-963.
12. O'Brien S, Moore JO, Boyd TE, Larratt LM, Skotnicki AB, Koziner B, et al., 5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen. J Clin Oncol 2009; 27:5208-12.
13. Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M, Trefzer U, et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 2006;24:4738-45.
14. Hellemans P, van Dam PA, Weyler J, van Oosterom AT, Buytaert P, Van Marck E. Prognostic value of bcl-2 expression in invasive breast cancer. Br J Cancer 1995;72:354-60.
15. Chen HH, Su WC, Guo HR, Chang TW, Lee WY. p53 and c-erbB-2 but not bcl-2 are predictive of metastasis-free survival in breast cancer patients receiving post-mastectomy adjuvant radiotherapy in Taiwan. Jpn J Clin Oncol 2002;32:332-9.
16. Elledge RM, Green S, Howes L, Clark GM, Berardo M, Allred DC, et al. bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study. J Clin Oncol 1997;15:1916-22.
17. Kim K, Chie EK, Han W, Noh DY, Park IA, Oh DY, et al. Prognostic value of p53 and bcl-2 expression in patients treated with breast conservative therapy. J Korean Med Sci 2010;25:235-9.
18. Ali HR, Dawson SJ, Blows FM, Provenzano E, Leung S, Nielsen T, et al. A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER-positive breast cancer. J Pathol 2012;226:97-107.
19. Lundin J, Lundin M, Holli K, Kataja V, Elomaa L, Pylkkänen L, et al. Omission of histologic grading from clinical decision making may result in overuse of adjuvant therapies in breast cancer: results from a nationwide study. J Clin Oncol 2001;19:28-36.
20. Trudeau ME, Pritchard KI, Chapman JA, Hanna WM, Kahn HJ, Murray D, et al. Prognostic factors affecting the natural history of node-negative breast cancer. Breast Cancer Res Treat 2005;89:35-45.
21. Ivshina AV, George J, Senko O, Mow B, Putti TC, Smeds J, et al. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res 2006;66:10292-301.
22. Schumacher M, Schmoor C, Sauerbrei W, Schauer A, Ummenhofer L, Gatzemeier W, et al. The prognostic effect of histological tumor grade in node-negative breast cancer patients. Breast Cancer Res Treat 1993;25: 235-45.
23. Roberti NE. The role of histologic grading in the prognosis of patients with carcinoma of the breast: is this a neglected opportunity? Cancer 1997;80:1708-16.